DSM Informs Market on Patheon N.V. PR Newswire HEERLEN, Netherlands, August 29, 2017 HEERLEN, Netherlands, August 29, 2017 /PRNewswire/ -- Royal DSM, a global science-based company active in...
Thermo Fisher Scientific Completes Acquisition of Patheon PR Newswire WALTHAM, Mass., Aug. 29, 2017 WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the...
Thermo Fisher Scientific Announces Receipt of All Required Regulatory Approvals for Proposed Acquisition of Patheon Tender Offer Scheduled to Expire at 5:00 p.m., New York City Time, on August...
Patheon N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (NYSE: PTHN) (“Patheon”), today announced that it has submitted written...
Thermo Fisher Scientific Prices Offering of Senior Notes PR Newswire WALTHAM, Mass., Aug. 10, 2017 WALTHAM, Mass., Aug. 10, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO...
Thermo Fisher Scientific Prices Offering of Common Stock PR Newswire WALTHAM, Mass., Aug. 8, 2017 WALTHAM, Mass., Aug. 8, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO) announced...
Thermo Fisher Scientific Announces $1.5 Billion Offering of Common Stock PR Newswire WALTHAM, Mass., Aug. 7, 2017 WALTHAM, Mass., Aug. 7, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:...
Thermo Fisher Extends Cash Tender Offer for All Outstanding Shares of Patheon to Coordinate Offer Timing with Two Remaining Regulatory Approvals Offer Now Scheduled to Expire at 5:00 p.m., New...
Investments in key service areas to meet growing customer demand Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the...
Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Patheon N.V. - PTHN PR Newswire NEW YORK, June 14, 2017 NEW YORK, June 14, 2017 /PRNewswire/ -- Juan Monteverde...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales